BDTX-1535 Strives to Overcome Intrinsic and Acquired EGFR Mutations in NSCLC and GBM

Patients with non–small cell lung cancer harboring acquired EGFR mutations, such as C797S and intrinsic mutations in EGFR represent underserved populations where additional targeted therapies are needed.

Related Keywords

Baltimore ,Maryland ,United States ,Boston ,Massachusetts ,Virginia ,Johns Hopkins ,Alexanderi Spira ,International Conference On Molecular ,Research Institute In Fairfax ,Virginia Cancer Specialists ,Research Institute ,Data Show Preliminary Efficacy ,Molecular Targets ,Cancer Therapeutics ,Cell Commun ,Egfr ,Nsclc ,C797s ,Glioblastoma Multiforme ,Bdtx 1535 ,Nct05256290 ,